Compare IPSC & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPSC | VNDA |
|---|---|---|
| Founded | 2019 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 405.8M | 361.4M |
| IPO Year | 2021 | 2005 |
| Metric | IPSC | VNDA |
|---|---|---|
| Price | $2.03 | $5.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $4.25 | ★ $14.90 |
| AVG Volume (30 Days) | ★ 926.1K | 798.6K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.30 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $109,164,000.00 | ★ $216,105,000.00 |
| Revenue This Year | N/A | $21.35 |
| Revenue Next Year | N/A | $37.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1556.76 | 8.72 |
| 52 Week Low | $0.44 | $4.14 |
| 52 Week High | $2.97 | $9.91 |
| Indicator | IPSC | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 41.12 | N/A |
| Support Level | $1.81 | N/A |
| Resistance Level | $2.62 | N/A |
| Average True Range (ATR) | 0.12 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 14.63 | 0.00 |
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.